FendX Technologies Inc - FDXTF STOCK NEWS

FendX Technologies (FDXTF) highlights recent CDC reports on the growing threat of antimicrobial resistance (AR). The CDC report from February 4, 2025, reveals that over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing at least 1.27 million deaths worldwide. The estimated cost to treat six common AR infections in healthcare settings exceeds US$4.6 billion annually.

The report notably identifies a concerning 5-fold increase in Candida auris cases from 2019 to 2022, with recent surges reported in New York, Georgia, and Florida. The CDC has classified this drug-resistant yeast as an 'urgent threat.'

In response, FendX is developing surface protection products, including their REPELWRAP™ film currently undergoing real-world testing. The company recently signed a letter of intent with US BioSolutions for acquiring IP and establishing a supply agreement for an eco-friendly microbe-trapping sponge.

FendX Technologies (FDXTF) has provided a comprehensive shareholder update highlighting significant developments. The company signed a letter of intent with US BioSolutions in November 2024 to manufacture an eco-friendly sponge and acquire two pending patents. The sponge, unlike traditional options, doesn't promote bacterial growth and is biodegradable.

In their nanotechnology portfolio, REPELWRAP™ film successfully completed pilot manufacturing at Dunmore International Inc. and showed positive results in its first real-world test, effectively repelling surface-dwelling bacteria including MRSA. The company plans to advance their medical catheter coating to preclinical studies in H2 2025.

On the financial front, FendX raised $710,005 through a private placement in March 2025 and plans a share-for-debt settlement of $68,000 at $0.17 per share. The company aims to finalize the eco-friendly sponge agreements, complete REPELWRAP™ testing, optimize spray formulation, and progress catheter coating development throughout 2025.

FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D), a nanotechnology company focused on surface protection coatings, has announced new equity compensation grants. The company has issued 2,925,000 stock options to directors, officers, employees and consultants at an exercise price of $0.17 with a five-year expiration term. Additionally, 500,000 restricted share units (RSUs) were granted to a consultant.

Both the stock options and RSUs vest immediately upon grant and are subject to a four-month and one-day hold period. These grants were made under the company's equity incentive plan dated October 19, 2021. The securities will not be registered under the U.S. Securities Act of 1933.

FendX Technologies (OTCQB: FDXTF) has announced positive initial results from real-world testing of its REPELWRAP™ film at a test site. The film, applied to a high-touch surface, maintained its repelling properties when tested against two surface-dwelling bacteria, including MRSA, as analyzed by McMaster University.

The company plans to conduct additional real-world performance testing of REPELWRAP™ film. Additionally, FendX has secured two strategic partnerships: a 12-month consulting agreement with a marketing firm for brand awareness services (pending financing), and a three-month agreement with Outside The Box Capital Inc. (OTB) for investor relations services at a fee of $288,000, with services expected to commence around March 19, 2025.

FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D), a nanotechnology company focused on surface protection coatings, has granted 55,000 restricted share units (RSUs) to a consultant. The RSUs will vest in three equal portions: on the grant date, December 20, 2024, and January 18, 2025. The grant follows the company's equity incentive plan from October 19, 2021, and includes a mandatory hold period of four months and one day from issuance.

FendX Technologies (CSE: FNDX) (OTCQB: FDXTF) has signed a non-binding LOI to acquire intellectual property including two patents related to BioFoam® technology and enter a supply agreement with US BioSolutions for eco-friendly sponge wipes. The transaction involves a US$75,000 cash payment and issuance of shares worth up to $200,000. The acquired technology offers washable, reusable sponge wipes that attract and trap pathogens when combined with cleaning agents. The deal is subject to conditions including due diligence, definitive agreements, regulatory approvals, and FendX completing a $1,000,000 financing.

FendX Technologies has been granted its fifth patent, specifically a US patent (No. 12,109,586) for its REPELWRAP™ film technology. The patent, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof', was registered on October 8, 2024. Licensed exclusively from McMaster University, it protects the company's nanotechnology for creating repellent surfaces that have demonstrated reduced bacterial and viral contamination in laboratory testing. This development follows recent pilot manufacturing runs with Dunmore for REPELWRAP™ film as the company prepares for real-world beta testing.

FendX Technologies has signed a Letter of Intent (LOI) with Sinelabs to explore a non-exclusive distribution agreement for FendX's future surface protection products in the United States. Sinelabs, a South Carolina-based company specializing in water treatment solutions, has an established sales network in healthcare, hospitality, and senior living facilities - markets that align with FendX's target sectors. The agreement remains subject to negotiation and execution of definitive agreements, successful product development, and regulatory approvals. REPELWRAP™ film, FendX's lead product, is expected to enter real-world testing soon.

FendX Technologies announces the grant of its Japanese patent on October 10, 2024, marking its fourth patent for REPELWRAP™ film technology. The patent, numbered JP7570358, titled 'Omniphobic Surfaces with Hierarchical Structures, and Methods of Making and Uses Thereof,' is exclusively licensed from McMaster University. The technology involves a fluoropolymer-containing material designed to reduce surface contamination by minimizing bacteria and virus adhesion. The company recently completed pilot manufacturing runs with Dunmore and is preparing for real-world beta testing.